215 related articles for article (PubMed ID: 28659588)
1. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo.
Huan Y; Jiang Q; Li G; Bai G; Zhou T; Liu S; Li C; Liu Q; Sun S; Yang M; Guo N; Wang X; Wang S; Liu Y; Wang G; Huang H; Shen Z
Sci Rep; 2017 Jun; 7(1):4351. PubMed ID: 28659588
[TBL] [Abstract][Full Text] [Related]
2. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
4. β-Cell Inactivation of
Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
[TBL] [Abstract][Full Text] [Related]
5. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.
Kim TH; Kim MK; Cheong YH; Chae YN; Lee Y; Ka SO; Jung IH; Shin CY; Bae EJ; Son MH
Eur J Pharmacol; 2016 Jan; 771():65-76. PubMed ID: 26621343
[TBL] [Abstract][Full Text] [Related]
6. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
Flock G; Baggio LL; Longuet C; Drucker DJ
Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280
[TBL] [Abstract][Full Text] [Related]
7. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
[TBL] [Abstract][Full Text] [Related]
8. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice.
Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y
Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743
[TBL] [Abstract][Full Text] [Related]
9. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.
Morita A; Mukai E; Hiratsuka A; Takatani T; Iwanaga T; Lee EY; Miki T
Endocrine; 2016 Mar; 51(3):429-39. PubMed ID: 26349938
[TBL] [Abstract][Full Text] [Related]
10. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
[TBL] [Abstract][Full Text] [Related]
11. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194
[TBL] [Abstract][Full Text] [Related]
12. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
Yoshida S; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
[TBL] [Abstract][Full Text] [Related]
14. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
15. Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.
Zhang Y; Wu M; Htun W; Dong EW; Mauvais-Jarvis F; Fonseca VA; Wu H
Sci Rep; 2017 Aug; 7(1):7964. PubMed ID: 28801559
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
Pugazhenthi S; Qin L; Bouchard R
Eur J Pharmacol; 2015 May; 755():42-9. PubMed ID: 25720341
[TBL] [Abstract][Full Text] [Related]
17. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
18. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
19. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
